Clinicians and patients continue to convey interest in personalized medicine. The objective of personalized medicine is to improve healthcare by tailoring disease prevention, diagnosis, and treatment strategies for individuals based on their unique clinical history and genetic composition. This article offers an overview of pharmacogenomics, discusses caveats specific to pharmacogenomics in pediatric populations, provides evidence-based recommendations for pediatric clinicians, and offers insight regarding the future role of pharmacogenomics testing in pediatric medicine. Reviews of the current literature and thoughtful discussions are presented regarding the pharmacogenomics of antidepressants, codeine and oncologic, asthma, and immunomodulatory pharmacotherapies.
PendergrassSABrown-GentryKDudekSM. The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery. Genet Epidemiol. 2011;35:410-422.
2.
ElieVde BeaumaisTFakhouryMJacqz-AigrainE. Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer, and anti-inflammatory drugs. Pharmacogenomics. 2011;12:827-843.
3.
HusainALoehleJAHeinDW. Clinical pharmacogenetics in pediatric patients. Pharmacogenomics. 2007;8:1403-1411.
4.
PaughSWStoccoGEvansWE. Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr. 2010;22:703-710.
5.
KennedyMJ. Pharmacogenomics and pediatric pharmacotherapy. In: Pharmacotherapy Self-Assessment Program PSAP-VII Book 4 Pediatrics. Lenexa, KS: American College of Clinical Pharmacy; 2010:7-23.
6.
BeckerML. Pharmacogenomics in pediatric rheumatology. Curr Opin Rheumatol. 2012;24:541-547.
YanagimachiMNarutoTHaraT. Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br J Clin Pharmacol. 2010;71:237-243.
9.
D’AngeloVRamagliaMIannottaA. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol. 2011;68:1339-1346.
10.
BeckerMLLeederJS. Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate. Hum Genomics and Proteomics. 2010;2010:257120.
11.
Lopez-LopezEMartin-GuerreroIBallesterosJGarcia-OradA. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2013;13:498-506.
12.
US Food and Drug Administration. Prograf (tacrolimus) capsules and injection. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). http://www.fda.gov/Safety/MedWatch/SafetyInformation. Last updated November1, 2013. Accessed January 17, 2014.
13.
ManickarajAKMitalS. Personalized medicine in pediatric cardiology: do little changes make a big difference?Curr Opin Pediatr. 2012;24:584-591.
14.
ElensLCapronAvan SchaikRH. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35:608-616.
15.
WechslerME. Managing asthma in the 21st century: the role of pharmacogenetics. Pediatr Ann. 2006;35:660-669.
16.
GuptaSAwasthiS. Pharmacogenomics of pediatric asthma. Indian J Hum Genet. 2010;16:111-118.
17.
LimaJJ. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther. 2007;11:97-104.
18.
Maitland-van der ZeeAHRaaijmakersJA. Variation at GLCCI1 and FCER2: one step closer to personalized asthma treatment. Pharmacogenomics. 2012;13:243-245.
19.
WallCACroarkinPESwintakCKoplinBA. Psychiatric pharmacogenomics in pediatric psychopharmacology. Child Adolesc Psychiatric Clin N Am. 2012;21:773-788.
20.
KronenbergSFrischARotbergBCarmelMApterAWeizmanA. Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics. 2008;9:1725-1736.
21.
KitzmillerJPGroenDKPhelpsMASadeeW. Pharmacogenomic testing: relevance in clinical practice why drugs work in some patients and not others. Cleve Clin J Med. 2011;78:243-257.
22.
OwleyTBruneCWSaltJ. A pharmacogenetic study of Escitalopram in autism spectrum disorders. Autism Res. 2010;3:1-7.
23.
JoycePRMulderRTLutySE. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein (BETA)3 subunit as predictors of response to fluoxetine and nortryptyline. Int J Neuropsychopharmacol. 2003;6:339-346.
